At Merck, Business Development As Usual?
Executive Summary
Merck's newly appointed SVP for world-wide licensing, C. David Nicholson, outlines the Big Pharma's dealmaking priorities at Elsevier Business Intelligence's February BIO-Windhover Pharmaceutical Strategic Outlook meeting.
You may also be interested in...
Merck Adds Flagship To Its Venture Fund Network
Merck contributes to Flagship’s latest fund, both sides promise to share ideas and expertise, but Merck gets no special rights to companies or products in Flagship’s portfolio.
Meet Merck’s Dealmaker: A Conversation With Roger Pomerantz
Merck’s new head of worldwide licensing and knowledge management Roger Pomerantz, MD, talks with IN VIVO about Merck’s business development strategy, whether biotech passion can exist on a Big Pharma scale, and the art of the deal.
Merck’s Capital Idea: Pharma’s Latest Attempt to Get Closer to VCs
Competition for biotech’s most eligible assets has never been stronger. As such, some pharmas are trying harder than ever to get in on the ground floor.